3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
5
Multiple Myeloma
2
Lymphoma
2
Hematologic Neoplasms
2
Colorectal Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Hemangiosarcoma
1
HER2-positive Metastatic Breast Cancer
1
HER2-Positive Primary Breast Cancer
1
Glioma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
Cyclophosphamide
11
fludarabine
8
Dexamethasone
7
pomalidomide
6
pembrolizumab
6
Rituximab
5
obinutuzumab
4
glofitamab
4
daratumumab
4
Immunotherapy, Adoptive
4
Gemcitabine
4
Bortezomib
4
venetoclax
3
selinexor
3
fludarabine phosphate
3
cemiplimab
3
Temozolomide
3
Nivolumab
3
Melphalan
3
Injections
3
Etoposide
3
zanubrutinib
2
tocilizumab
2
pirtobrutinib
2
blinatumomab
2
abemaciclib
2
Sirolimus
2
Oxaliplatin
2
Mesna
2
Lisaftoclax
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Recurrence
×
Ado-Trastuzumab Emtansine
×
30 days
×
Clear all
No trials found.